Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carrie Mendivil - IR Sujal Patel - Co-Founder & CEO Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - CFO Conference Call Participants Yuko Oku - Morgan Stanley Daniel Brennan - Cowen Ivy Kozlowski - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q (Mark One) For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. Indicate by check mark whether the registrant is a large accelerated filer ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Carrie Mendivil - Investor Relations Sujal Patel - Co-Founder, Chief Executive Officer, President, Secretary & Director Parag Mallick - Co-Founder, Chief Scientist & Director Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dave Delahunt - Goldman Sachs Dan Brennan - Cowen Operator Thank you for standing by, and welcome to the Nautilus Biotechn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 98-154172 ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Carrie Mendivil - Investor Relations Sujal Patel - Co-Founder, Chief Executive Officer, President, Secretary & Director Anna Mowry - Chief Financial Officer Parag Mallick - Co-Founder, Chief Scientist & Director Conference Call Participants Yuko Oku - Morgan Stanley Daniel Brennan - Cowen Matt Sykes - Goldman Sachs Operator Good morning and thank you for standing by. Welcome to the Nautilu ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Sujal Patel - Co-Founder and CEO Anna Mowry - CFO Parag Mallick - Co-Founder and Chief Scientist Conference Call Participants Max Masucci - Cowen and Company Matthew Sykes - Goldman Sachs Brandon Couillard - Jefferies Tejas Savant - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 and Full Year 2022 earnings conference call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact nam ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 98-15 ...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder and CEO Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - CFO Conference Call Participants Max Masucci - Cowen David Delahunt - Goldman Sachs Brandon Couillard - Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Nautilus Q3 2022 Earnings Call. [Operator Instructions] I would now like to turn the call over to your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant ...